In the retrospective HERMIONE 9 study, in which real‐world data from 87 patients (including 60 postmenopausal patients) with ER‐positive HER2‐positive advanced breast cancer treated with F500 plus trastuzumab were analyzed, progression‐free survival (PFS) was 12.9 months and 77% of patients had been treated using three or more previous therapies (both chemotherapy and endocrine therapy with or without anti‐HER2 therapy).12 This evidence concerns the gene ERBB2 and breast carcinoma.